NASDAQ:ZNTL Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis $4.36 +0.20 (+4.81%) (As of 09/19/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Zentalis Pharmaceuticals alerts: Email Address About Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ZNTL alerts:Sign Up Key Stats Today's Range$4.21▼$4.4650-Day Range$2.90▼$4.5752-Week Range$2.83▼$23.12Volume1.97 million shsAverage Volume1.30 million shsMarket Capitalization$310.04 millionP/E RatioN/ADividend YieldN/APrice Target$10.78Consensus RatingHold Company OverviewZentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.Read More… Why You Should NOT Trade This Market (Ad)You'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this different from every other options research you may have seen? Well, for starters... most of them want you to first BUY their service... which is usually thousands of dollars...Just click here to get the full details on the 5-Day Options Trading Challenge, before this offer go Zentalis Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 31st PercentileZentalis Pharmaceuticals scored higher than 31% of companies evaluated by MarketBeat, and ranked 849th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingZentalis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 3 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageZentalis Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Zentalis Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Zentalis Pharmaceuticals are expected to decrease in the coming year, from ($2.95) to ($3.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zentalis Pharmaceuticals is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zentalis Pharmaceuticals is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZentalis Pharmaceuticals has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Zentalis Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.27% of the outstanding shares of Zentalis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverZentalis Pharmaceuticals has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Zentalis Pharmaceuticals has recently increased by 6.14%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZentalis Pharmaceuticals does not currently pay a dividend.Dividend GrowthZentalis Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.27% of the outstanding shares of Zentalis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverZentalis Pharmaceuticals has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Zentalis Pharmaceuticals has recently increased by 6.14%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.38 News SentimentZentalis Pharmaceuticals has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Zentalis Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest15 people have searched for ZNTL on MarketBeat in the last 30 days. MarketBeat FollowsOnly 3 people have added Zentalis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zentalis Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.10% of the stock of Zentalis Pharmaceuticals is held by insiders.Read more about Zentalis Pharmaceuticals' insider trading history. Receive ZNTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ZNTL Stock News HeadlinesBiotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on UpdatesSeptember 19 at 10:18 PM | msn.comFDA lifts partial clinical hold on Zentalis Pharma’s cancer WEE1 inhibitorSeptember 18 at 8:26 PM | msn.comHave you heard of this 5-Day Challenge yet?You'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this different from every other options research you may have seen? Well, for starters... most of them want you to first BUY their service... which is usually thousands of dollars...September 19, 2024 | InvestorPlace (Ad)Maintaining Hold on Zentalis Pharmaceuticals Amidst Positive Regulatory Developments and Upcoming Clinical MilestonesSeptember 18 at 3:24 PM | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)September 18 at 10:23 AM | markets.businessinsider.comZentalis Pharmaceuticals' (ZNTL) "Outperform" Rating Reaffirmed at OppenheimerSeptember 18 at 3:39 AM | americanbankingnews.comZentalis Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:ZNTL)September 18 at 2:43 AM | americanbankingnews.comZentalis Pharma (NASDAQ:ZNTL) Stock Quotes, Forecast and News SummarySeptember 17 at 2:24 PM | benzinga.comSee More Headlines ZNTL Stock Analysis - Frequently Asked Questions How have ZNTL shares performed this year? Zentalis Pharmaceuticals' stock was trading at $15.15 at the beginning of the year. Since then, ZNTL shares have decreased by 71.2% and is now trading at $4.36. View the best growth stocks for 2024 here. How were Zentalis Pharmaceuticals' earnings last quarter? Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) announced its earnings results on Friday, August, 9th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.84) by $0.40. When did Zentalis Pharmaceuticals IPO? Zentalis Pharmaceuticals (ZNTL) raised $131 million in an initial public offering (IPO) on Friday, April 3rd 2020. The company issued 7,700,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO. Who are Zentalis Pharmaceuticals' major shareholders? Top institutional investors of Zentalis Pharmaceuticals include Decheng Capital LLC (4.32%), Primecap Management Co. CA (1.74%), Renaissance Technologies LLC (0.93%) and Dimensional Fund Advisors LP (0.88%). Insiders that own company stock include Matrix Capital Management Comp, Anthony Y Sun, Cam Gallagher, Melissa B Epperly, Diana Hausman, Kimberly Blackwell, David Michael Johnson, Carrie Brownstein, Jan Skvarka, Kevin D Bunker, Dimitris Voliotis and Alexis Pinto. View institutional ownership trends. How do I buy shares of Zentalis Pharmaceuticals? Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Zentalis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zentalis Pharmaceuticals investors own include Esperion Therapeutics (ESPR), Zogenix (ZGNX), AbbVie (ABBV), Advanced Micro Devices (AMD), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY) and Clovis Oncology (CLVS). Company Calendar Last Earnings8/09/2024Today9/19/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZNTL CUSIPN/A CIK1725160 Webwww.zentalis.com Phone212-433-3791FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Stock Price Target$10.78 High Stock Price Target$20.00 Low Stock Price Target$4.00 Potential Upside/Downside+147.2%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-292,190,000.00 Net MarginsN/A Pretax Margin-479.32% Return on Equity-44.22% Return on Assets-35.61% Debt Debt-to-Equity RatioN/A Current Ratio6.59 Quick Ratio6.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.18 per share Price / Book0.71Miscellaneous Outstanding Shares71,110,000Free Float66,693,000Market Cap$310.04 million OptionableOptionable Beta1.70 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report This page (NASDAQ:ZNTL) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredForget ChatGPT: Follow the AI Retirement PlaybookEveryone’s talking about AI right now, but I’ve been talking about it for years. Follow this two-part playb...Brownstone Research | SponsoredDump Nvidia, Apple, and Tesla Before It’s Too LateThe financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumpi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.